Our Technologies

Read about our available technologies and get in touch with our team




Clear all filters

A cellular therapy to locally deliver nitric oxide (NO) to the conventional aqueous humour outflow pathway, thereby lowering eye pressure and preserving vision in glaucoma.
A fast, achromatic, and light-efficient optical system that can record super-resolved Structured Illumination Microscopy (SIM) images at very high speeds, using only a single moving part.
A CRISPR-based platform for inducibly up- and down-regulating up to 24 genes in the yeast, Saccharomyces cerevisiae.
Novel heme oxygenase 1 (HO-1) probe compositions, and methods covering easy-to-use and rapid readouts of cell protection in cardiovascular diseases, hemorrhage and red cell disorders.
A technique to minimize or eliminate damage created during the insertion of cochlear implants.
Nanofiller/polymer composites films with enhanced thermal conductivity for use in thermal management, energy storage and electronic packaging
Methods for use in extracellular vesicle (EV), including exosomes, isolation and engineering applications broadly encompassing EV manufacturing, therapeutic, medical and diagnostics uses.
An injector to reduce the damage to biological materials such as cells during an injection process and improve the survivability of the biological materials
novel oligonucleotides that bind to H19, displacing Let-7 miRNAs, leading to a reduction in inflammation in muscle tissues, and consequently a reduction in muscle wasting.
A novel growth medium for the culture of Lactobacillus iners to unprecedented high cell densities within 24 hours.

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Licensing and IP performance 2019/20

Inventions disclosed

Imperial inventors submitted 250 invention disclosures to our IPC team during the year

Active licences

Imperial College London's licensing portfolio comprises 244 licences

Patents filed

Imperial filed 137 patents (including PCT applications) during the year

Patent portfolio

Imperial's patent portfolio reached 331 patents during the year

Upcoming Events

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Latest News

Accelerated development of a potential treatment for cystic fibrosis

Accelerated development of a potential treatment for cystic fibrosis

The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more

Natural Killer – licensing a cell therapy

Natural Killer – licensing a cell therapy

Imperial has licensed iNKT cell technology based on research by Prof. Tassos Karadimitris to SUDA Pharmaceuticals. Find out more

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial partner Apollo receives £100m to boost medical research at leading unis

Imperial will benefit from continued support for translational biomedical research under a unique technology transfer model. Find out more